(BAYN) Bayer NA - Ratings and Ratios

Exchange: XETRA • Country: Germany • Currency: EUR • Type: Common Stock • ISIN: DE000BAY0017

BAYN: Medicines, Drugs, Seeds, Therapies, Supplements, Chemicals

Bayer Aktiengesellschaft is a global life science powerhouse, operating at the intersection of healthcare and agriculture. Its diversified business model is divided into three core segments: Pharmaceuticals, Consumer Health, and Crop Science.

The Pharmaceuticals division is the companys largest revenue generator, focusing on innovative treatments for critical areas such as cardiology, womens health, oncology, and ophthalmology. It also develops cutting-edge therapies in cell and gene therapy, positioning Bayer as a leader in next-generation medical treatments. Strategic collaborations with institutions like MD Anderson Cancer Center and Dewpoint Therapeutics underscore its commitment to advancing oncology and cardiovascular therapies.

The Consumer Health segment is a staple in everyday healthcare, offering a broad portfolio of over-the-counter medications, skincare products, and nutritional supplements. This division caters to widespread health needs, from pain management and digestive health to allergy relief, making it a reliable contributor to Bayers steady cash flow.

Crop Science is Bayers agricultural arm, providing farmers with high-tech solutions to enhance yields and sustainability. This includes seed technology, pest control, and digital farming tools. The segments focus on innovation addresses global food security challenges, aligning with the growing demand for efficient agricultural practices.

Bayers extensive distribution network ensures its products reach a wide audience, from pharmacies and supermarkets to hospitals and farmers. Its collaborations with academic institutions and biotech firms highlight a commitment to R&D, crucial for long-term growth in competitive markets.

Founded in 1863, Bayers legacy is built on scientific excellence and innovation. Headquartered in Leverkusen, Germany, the company continues to be a key player in global healthcare and agriculture. For more information, visit https://www.bayer.com.

Ticker Symbol: BAYN | Exchange: XETRA | Type: Common Stock | Country Origin: Germany | GICS Sub Industry: Pharmaceuticals

Market Cap: 21,259.66M EUR | P/E: 0.00 | Forward P/E: 1.65 | P/B: 0.70 | P/S: 0.45

Additional Sources for BAYN Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

BAYN Stock Overview

Market Cap in USD 25,613m
Sector Healthcare
Industry Drug Manufacturers - General
GiC Sub-Industry Pharmaceuticals
IPO / Inception

BAYN Stock Ratings

Growth 5y -61.7%
Fundamental -14.9%
Dividend 0.61%
Rel. Strength -20.8
Analysts -
Fair Price Momentum 20.65 EUR
Fair Price DCF 95.28 EUR

BAYN Dividends

Dividend Yield 12m 0.91%
Yield on Cost 5y 0.49%
Annual Growth 5y -47.66%
Payout Consistency 85.9%

BAYN Growth Ratios

Growth Correlation 3m 85.5%
Growth Correlation 12m -70.1%
Growth Correlation 5y -53.7%
CAGR 5y -12.95%
CAGR/Max DD 5y -0.18
Sharpe Ratio 12m -0.31
Alpha -27.74
Beta 1.045
Volatility 34.05%
Current Volume 2372.5k
Average Volume 20d 4227.1k
What is the price of BAYN stocks?
As of April 02, 2025, the stock is trading at EUR 22.32 with a total of 2,372,540 shares traded.
Over the past week, the price has changed by -5.32%, over one month by -7.02%, over three months by +15.10% and over the past year by -19.97%.
Is Bayer NA a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Bayer NA is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -14.91 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BAYN as of April 2025 is 20.65. This means that BAYN is currently overvalued and has a potential downside of -7.48%.
Is BAYN a buy, sell or hold?
Bayer NA has no consensus analysts rating.
What are the forecast for BAYN stock price target?
According to ValueRays Forecast Model, BAYN Bayer NA will be worth about 22.3 in April 2026. The stock is currently trading at 22.32. This means that the stock has a potential downside of -0.09%.
Issuer Forecast Upside
Wallstreet Target Price 28.1 25.7%
Analysts Target Price - -
ValueRay Target Price 22.3 -0.1%